EOLS - Evolus Announces Participation in September Investment Conferences
NEWPORT BEACH, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in two investment conferences in September.
| Event : |
| H.C. Wainwright 23 rd Annual Global Investment Conference |
| Date : |
| Monday, September 13, 2021 |
| Time: |
| Available on-demand starting at 7:00am ET |
| Event : |
| Cantor 2021 Virtual Global Healthcare Conference |
| Date : |
| Tuesday, September 28, 2021 |
| Time: |
| 3:20pm ET |
Audio webcasts of these events will be available on the investor relations section of Evolus’ website at www.evolus.com . Replays of the webcasts will be available for 90 days after the date of each presentation.
About Evolus, Inc.
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. Approved in 2019 by the U.S. Food and Drug Administration, Jeuveau® (prabotulinumtoxinA-xvfs) is the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus’ unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at www.evolus.com .
Jeuveau ® is a registered trademark of Evolus, Inc.
Hi-Pure ™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Evolus, Inc. Contacts:
Investor Contact:
David K. Erickson, Evolus, Inc.
Vice President, Investor Relations
Tel: 949-966-1798
Email: david.erickson@evolus.com
Media Contact:
Crystal Muilenburg, Evolus, Inc.
Chief Marketing Officer
Tel: 949-284-4506
Email: media@evolus.com